ArticleAntibiotics (Basel, Switzerland)2022
Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- MappingAntibiotics (Basel, Switzerland) · 2026Article
- Molecular Insights into the MdtABC Efflux Pump Genes in ClinicalCurrent pharmaceutical design · 2026Article
- Computational Evaluation ofCurrent computer-aided drug design · 2026Article
- Similarities in the consumption trajectory of antibacterial drugs in the outpatient care sector in Germany from 1986 to 2022: identification of shared patterns, correlation analysis of prescribed defined daily dose and assessment of underlying influences.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Comprehensive Molecular Profiling of AcrAB-TolC Efflux Pump Genes in Salmonella typhi Isolates from Typhoid Infected Patients.Current microbiology · 2025Article
- New Perspectives on Antimicrobial Agents: Pivmecillinam.Antimicrobial agents and chemotherapy · 2025Review
- Antimicrobial resistance burden in India and Germany in 2022: A systematic analysis along with One Health perspective.Heliyon · 2024Article
- Effectiveness of selective antibiotics use in ESBL-related UTIs.BMC microbiology · 2024Article
- Recurrent Cystitis in Women-A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy.Antibiotics (Basel, Switzerland) · 2024Article
- Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens.Open forum infectious diseases · 2024Review
- Letter to the editor: Antimicrobial resistance data and treatment guidelines - challenges in the context of urine samples and mecillinam testing.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Prior Antibiotic Use Increases Risk of Urinary Tract Infections Caused by ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Molecular Characterization of Extended Spectrum β-Lactamase (ESBL) and Virulence Gene-Factors in UropathogenicAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Urinary tract infections (UTIs) are among the most common bacterial infections in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.